Health Canada authorizes the use of the Pfizer-BioNTech Comirnaty COVID-19 vaccine as a booster shot
November 9, 2021 | Ottawa, ON | Health Canada
Health Canada has authorized the use of the Pfizer-BioNTech Comirnaty COVID-19 vaccine as a booster shot.
A COVID-19 booster shot is an extra dose of the vaccine given after completion of the primary vaccine series. The booster shot is designed to help people maintain their protection against COVID-19 over time.
Health Canada received Pfizer's submission to approve a booster on October 1, 2021. After a thorough, independent review of the evidence, Health Canada has determined that the Comirnaty COVID-19 vaccine booster shot meets the Department's stringent safety, efficacy and quality requirements.
The booster is authorized for adults 18 years of age and older, to be used at least six months after an individual has completed their primary vaccine series. The Comirnaty COVID-19 booster is a full dose of the regular vaccine (30 mcg).
Evidence continues to show that being fully vaccinated provides strong protection against serious illness, hospitalization and death from COVID-19, including against the Delta variants.
People in Canada should consult their local public health guidance, informed by the National Advisory Committee on Immunization, for details on which individuals or groups of people are recommended to receive a booster dose at this time.
For information on authorized vaccines and treatments in Canada, visit the COVID-19 vaccines and treatments portal.
Report a problem or mistake on this page
- Date modified: